Tvardi Therapeutics, Inc. (TVRD)Healthcare | Biotechnology | Sugar Land, United States | NasdaqCM
3.39 USD
+0.17
(5.280%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 3.38 -0.01 (-0.014%) ⇩ (April 17, 2026, 5:56 p.m. EDT) Short-term: ★☆☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 4:14 p.m. EDT
Tvardi Therapeutics (TVRD) is currently in a deep correction, with a price significantly below its 52-week high and recent earnings misses contributing to the decline. The stock has been heavily shorted, and while there are some signs of retail interest, the fundamentals remain weak, with negative earnings and a high overall risk profile. The options market is not showing strong directional signals, and the lack of dividend payouts makes it unsuitable for income-focused investors. Short-term traders might consider the recent dip as a potential buying opportunity, but the high risk and lack of positive momentum suggest caution. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.165240 |
| AutoTheta | 0.233576 |
| AutoETS | 0.233714 |
| MSTL | 0.238367 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 46% |
| H-stat | 6.45 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.348 |
| Excess Kurtosis | -0.21 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.96 |
| Market Cap | 31,802,760 |
| Forward P/E | -1.38 |
| Website | https://tvarditherapeutics.com |
As of April 11, 2026, 4:14 p.m. EDT: Options speculators are predominantly buying out-of-the-money (OTM) calls and puts, indicating a lack of consensus on the short-term direction of TVRD. The high implied volatility (IV) on calls, especially for expirations like 2026-06-18, suggests some traders are anticipating a potential upward move, although the current price is significantly below the 52-week high. However, the low volume and open interest (OI) for both calls and puts suggest limited conviction in either direction. The presence of OTM puts with higher OI might indicate some caution, but the overall activity does not signal a strong bearish or bullish sentiment.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.815684 |
| Address1 | 3 Sugar Creek Center Boulevard |
| Address2 | Suite 525 |
| All Time High | 1,067.292 |
| All Time Low | 2.75 |
| Ask | 3.45 |
| Ask Size | 1 |
| Audit Risk | 7 |
| Average Analyst Rating | 2.0 - Buy |
| Average Daily Volume10 Day | 59,700 |
| Average Daily Volume3 Month | 54,149 |
| Average Volume | 54,149 |
| Average Volume10Days | 59,700 |
| Bid | 3.31 |
| Bid Size | 1 |
| Board Risk | 3 |
| Book Value | 2.233 |
| City | Sugar Land |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.39 |
| Current Ratio | 2.856 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 3.39 |
| Day Low | 3.22 |
| Debt To Equity | 0.96 |
| Display Name | Tvardi Therapeutics |
| Earnings Timestamp | 1,774,987,200 |
| Earnings Timestamp End | 1,778,702,400 |
| Earnings Timestamp Start | 1,778,702,400 |
| Ebitda | -26,653,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.045 |
| Enterprise Value | 1,192,756 |
| Eps Current Year | -2.035 |
| Eps Forward | -2.45333 |
| Eps Trailing Twelve Months | -3.26 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.5559 |
| Fifty Day Average Change | -0.16589999 |
| Fifty Day Average Change Percent | -0.04665485 |
| Fifty Two Week Change Percent | -81.568405 |
| Fifty Two Week High | 43.65 |
| Fifty Two Week High Change | -40.260002 |
| Fifty Two Week High Change Percent | -0.92233676 |
| Fifty Two Week Low | 2.75 |
| Fifty Two Week Low Change | 0.6400001 |
| Fifty Two Week Low Change Percent | 0.2327273 |
| Fifty Two Week Range | 2.75 - 43.65 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,391,178,600,000 |
| Float Shares | 6,461,494 |
| Forward Eps | -2.45333 |
| Forward P E | -1.3817954 |
| Free Cashflow | -15,216,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 12 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.34660998 |
| Held Percent Institutions | 0.30165002 |
| Implied Shares Outstanding | 9,381,345 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,744,761,600 |
| Last Split Factor | 1:3 |
| Long Business Summary | Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas. |
| Long Name | Tvardi Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 31,802,760 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_570288312 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -18,214,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 31,662,036 |
| Number Of Analyst Opinions | 6 |
| Open | 3.27 |
| Operating Cashflow | -23,499,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 713 489 8654 |
| Post Market Change | -0.014300108 |
| Post Market Change Percent | -0.42183208 |
| Post Market Price | 3.3757 |
| Post Market Time | 1,776,462,968 |
| Previous Close | 3.22 |
| Price Eps Current Year | -1.6658477 |
| Price Hint | 4 |
| Price To Book | 1.5181371 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.79 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.0 |
| Region | US |
| Regular Market Change | 0.17 |
| Regular Market Change Percent | 5.27951 |
| Regular Market Day High | 3.39 |
| Regular Market Day Low | 3.22 |
| Regular Market Day Range | 3.22 - 3.39 |
| Regular Market Open | 3.27 |
| Regular Market Previous Close | 3.22 |
| Regular Market Price | 3.39 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 35,790 |
| Return On Assets | -0.49701 |
| Return On Equity | -2.37812 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 9,381,344 |
| Shares Percent Shares Out | 0.069699995 |
| Shares Short | 668,566 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 636,750 |
| Short Name | Tvardi Therapeutics, Inc. |
| Short Ratio | 14.19 |
| Source Interval | 15 |
| State | TX |
| Symbol | TVRD |
| Target High Price | 15.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 8.33333 |
| Target Median Price | 8.0 |
| Total Cash | 30,811,000 |
| Total Cash Per Share | 3.284 |
| Total Debt | 201,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.26 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 13.34195 |
| Two Hundred Day Average Change | -9.95195 |
| Two Hundred Day Average Change Percent | -0.74591416 |
| Type Disp | Equity |
| Volume | 35,790 |
| Website | https://tvarditherapeutics.com |
| Zip | 77,478 |